The CLARITY-PanTumor01 study, an ongoing phase II trial with multiple substudies, is evaluating the use of AZD0901 in patients with CLDN18.2-positive advanced solid tumors, including GC/GEJC, PC, and BTCs [65]. The gene discussed is CLDN18; the disease is gastric cancer.